Edward Jordan
Corporate Officer/Principal en XSPRAY PHARMA AB .
Fortuna: - $ al 31/03/2024
Perfil
Edward P.
Jordan is currently the Chief Commercial Officer at Xspray Pharma AB since 2023.
Prior to this, he was the Chief Commercial Officer at Humanigen, Inc. from 2020 to 2023 and Senior Vice President at DBV Technologies, Inc. from 2016 to 2020.
He also held a senior leadership position at AMAG Pharmaceuticals, Inc. Mr. Jordan has an undergraduate degree from the University of Rhode Island and an MBA from Southern New Hampshire University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
HUMANIGEN INC
0.01% | 11/04/2023 | 12 500 ( 0.01% ) | 0 $ | 31/03/2024 |
Cargos activos de Edward Jordan
| Empresas | Cargo | Inicio |
|---|---|---|
| XSPRAY PHARMA AB | Corporate Officer/Principal | 15/09/2023 |
Antiguos cargos conocidos de Edward Jordan.
| Empresas | Cargo | Fin |
|---|---|---|
| HUMANIGEN, INC. | Corporate Officer/Principal | 14/09/2023 |
DBV Technologies, Inc.
 DBV Technologies, Inc. Medical/Nursing ServicesHealth Services Part of DBV Technologies SA, DBV Technologies, Inc. provides medical care services. The private company is based in New York, NY. | Corporate Officer/Principal | 24/08/2020 |
| AMAG PHARMACEUTICALS, INC. | Sales & Marketing | - |
Formación de Edward Jordan.
| University of Rhode Island | Undergraduate Degree |
| Southern New Hampshire University | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| HUMANIGEN, INC. | Health Technology |
| XSPRAY PHARMA AB | Health Technology |
| Empresas privadas | 2 |
|---|---|
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
DBV Technologies, Inc.
DBV Technologies, Inc. Medical/Nursing ServicesHealth Services Part of DBV Technologies SA, DBV Technologies, Inc. provides medical care services. The private company is based in New York, NY. | Health Services |
- Bolsa de valores
- Insiders
- Edward Jordan
